Clinical trial NCT02939859 - References

Multiple Sclerosis — Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,Autoimmune, Inflammatory, Neurologic Conditions

Citation(s)

•   Ascherio A, Munger KL
  Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol. 2007 Apr;61(4):288-99. Review.
•   Balak DM, Hengstman GJ, Çakmak A, Thio HB
  Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review. Mult Scler. 2012 Dec;18(12):1705-17. doi: 10.1177/1352458512438239. Epub 2012 Feb 27. Review.
•   Bates D
  Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology. 2011 Jan 4;76(1 Suppl 1):S14-25. doi: 10.1212/WNL.0b013e3182050388. Review.
•   Comi G
  Treatment of multiple sclerosis: role of natalizumab. Neurol Sci. 2009 Oct;30 Suppl 2:S155-8. doi: 10.1007/s10072-009-0147-2. Review.
•   Dyment DA, Ebers GC, Sadovnick AD
  Genetics of multiple sclerosis. Lancet Neurol. 2004 Feb;3(2):104-10. Review.
•   Farinotti M, Vacchi L, Simi S, Di Pietrantonj C, Brait L, Filippini G
  Dietary interventions for multiple sclerosis. Cochrane Database Syst Rev. 2012 Dec 12;12:CD004192. doi: 10.1002/14651858.CD004192.pub3. Review. Update in: Cochrane Database Syst Rev. 2020 May 19;5:CD004192.
•   Freedman MS
  Long-term follow-up of clinical trials of multiple sclerosis therapies. Neurology. 2011 Jan 4;76(1 Suppl 1):S26-34. doi: 10.1212/WNL.0b013e318205051d. Review.
•   Hassan-Smith G, Douglas MR
  Epidemiology and diagnosis of multiple sclerosis. Br J Hosp Med (Lond). 2011 Oct;72(10):M146-51. Review.
•   Hassan-Smith G, Douglas MR
  Management and prognosis of multiple sclerosis. Br J Hosp Med (Lond). 2011 Nov;72(11):M174-6. Review.
•   He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S
  Teriflunomide for multiple sclerosis. Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;3:CD009882.
•   Huntley A
  A review of the evidence for efficacy of complementary and alternative medicines in MS. Int MS J. 2006 Jan;13(1):5-12, 4. Review.
•   Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH
  Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28.
•   Luessi F, Siffrin V, Zipp F
  Neurodegeneration in multiple sclerosis: novel treatment strategies. Expert Rev Neurother. 2012 Sep;12(9):1061-76; quiz 1077. doi: 10.1586/ern.12.59. Review.
•   Manouchehrinia A, Constantinescu CS
  Cost-effectiveness of disease-modifying therapies in multiple sclerosis. Curr Neurol Neurosci Rep. 2012 Oct;12(5):592-600. doi: 10.1007/s11910-012-0291-6. Review.
•   Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G
  Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013 May 31;(5):CD002127. doi: 10.1002/14651858.CD002127.pub3. Review.
•   Miller AE
  Multiple sclerosis: where will we be in 2020? Mt Sinai J Med. 2011 Mar-Apr;78(2):268-79. doi: 10.1002/msj.20242. Review.
•   Nakahara J, Maeda M, Aiso S, Suzuki N
  Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy. Clin Rev Allergy Immunol. 2012 Feb;42(1):26-34. doi: 10.1007/s12016-011-8287-6. Review.
•   Olsen SA
  A review of complementary and alternative medicine (CAM) by people with multiple sclerosis. Occup Ther Int. 2009;16(1):57-70. doi: 10.1002/oti.266. Review.
•   Tsang BK, Macdonell R
  Multiple sclerosis- diagnosis, management and prognosis. Aust Fam Physician. 2011 Dec;40(12):948-55.
•   Weinshenker BG
  Natural history of multiple sclerosis. Ann Neurol. 1994;36 Suppl:S6-11. Review.

Use of Cellular Stromal Vascular Fraction (cSVF) for Select Multiple Sclerosis, Autoimmune, Inflammatory, and Neurologic Conditions: Clinical Interventional Study of Adverse Events and Clinical Outcomes Using Autologous Stem-Stromal Cells.

Details for clinical trial NCT02939859